08.00

E. Souied FRANCE
Stagardt and FFM

08.12

G. Querques FRANCE
Best and AOFVD

08.24

S. Mohand Said FRANCE
Cone dystrophy

08.36

N. Leveziel FRANCE
Pattern dystrophy

08.48

I. Audo FRANCE
X-linked retinoschisis

09.00

E. Souied FRANCE
Inherited white dots on the retina

09.12

Discussion

09.30

End of course

08.00

C. Delaey BELGIUM
How to get the most out of your spectral domain OCT

08.20

A. Erginay FRANCE
Interpretation of the scans

08.40

A. Gaudric FRANCE
Diagnostic signs

09.00

Discussion

09.30

End of course

08.00

S. Aldington UK
Diabetic retinopathy grading systems: Which one to use?

08.20

P. Scanlon UK
Update on the English National Programme

08.40

R. Johnston UK
Electronic data collection in diabetic retinopathy screening

09.00

C. Egan UK
Difficult cases

09.20

Discussion

09.30

End of course

08.00

B. Corcostegui SPAIN
Advantages of angiography with wide field systems

08.12

F. Bandello ITALY
Is the operator important in the OCT examination of exudative age-related macular degeneration?

08.24

J. Cunha-Vaz PORTUGAL
Patients do not love fluorscein angiography, do we really need it nowadays?

08.36

P. Massin FRANCE
Spectral domain optical coherence tomography in diabetic macular edema

08.48

R. Navarro SPAIN
Fundus Autofluorescence

09.00

F. Holz GERMANY
Diagnosis of macular telangiectasia type 2

09.12

M. Battaglia Parodi ITALY
Near-infrared autofluorescence in age-related macular degeneration

09.24

Discussion

09.30

End of course

11.00

A. Laidlaw UK
Introduction

11.02

L. Downey UK
Pathophysiology of proliferative diabetic retinopathy

11.14

M. Mohamed UK
Classification and natural history of proliferative retinopathy

11.26

S. Mann UK
Screening for proliferative diabetic retinopathy

11.38

R. Wong UK
Initial treatment of proliferative diabetic retinopathy

11.50

S. Mann UK
Judging response, further laser, complications

12.02

T. Williamson UK
Progression to vitreous haemorrhage and TRD

12.14

A. Laidlaw UK
Anti VEGF therapy for proliferative diabetic retinopathy

12.30

End of course

11.00

Introduction

11.10

C. Mateo SPAIN
Myopic macula…new concepts old treatments

11.20

B. Corcostegui SPAIN
Options in the dissection of proliferative diabetic retinopathy

11.30

J. Garcia Arumi SPAIN
Is combo surgery better for our patients?

11.40

S. Rizzo ITALY
How the new technologies influence our surgical techniques in diabetic trational retinal detachment

11.50

B. Aylward UK
Achieving success vitrectomy for retinal detachment

12.00

Discussion: Cases ‘complications and complexities’

12.30

End of course

14.30

G. Holder UK
An introduction to the tests

14.50

B. Leroy BELGIUM
Inherited retinal disease and electrophysiology

15.10

G. HolderUK
Electrophysiology in acquired retinal disease

15.30

M. Hawlina SLOVENIA
The integration of electrophysiology and imaging

15.50

Discussion

16.00

End of course

14.30

I. Corcostegui SPAIN
Risk factors

14.42

B. Corcostegui SPAIN
Lensectomy and pseudophakic management

14.54

C. Mateo SPAIN
Membrane peeling

15.06

J. Garcia Arumi SPAIN
Relaxing retinotomy

15.18

J. Garcia Arumi SPAIN
Subretinal PVR

15.30

B. Aylward UK
Fluid-gas or fluid silicon oil exchange

15.42

A. Adan SPAIN
Discussion

16.00

End of course

14.30

A. Polito ITALY
Introduction and course objective

14.32

P. Massin FRANCE
New spectral domain OCT microstructural changes relevant to clinical outcomes in diabetic macular edema

14.44

D. Gaucher FRANCE
OCT and traumatic maculopathy

14.56

M.G. Cereda ITALY
Full thickness vs lamellar macular hole formation: new data provided by spectral domain OCT and implications for surgery.

15.08

C. Ahlers AUSTRIA
Imaging RPE disease in AMD: Possibilities and limitations of current imaging modalities

15.20

A. Polito ITALY
Quantitative vs qualitative OCT analysis in neovascular AMD

15.32

Discussion

16.00

End of course

16.30

Welcome

16.33

G.E. Quinn USA
ROP: a global perspective

16.45

K. Tawansky USA
Classification, screening, treatment guidelines and
complications

16.57

A. Ells CANADA
Telemedicine: the new standard of care for ROP screening

17.09

M. Shapiro USA
Controversies in ROP AP-ROP

17.21

P. Dorta CHILE
Anti-VEGF drugs in ROP

17.33

K. Drenser USA
Vitreoretinal surgery in ROP

17.45

Discussion: Latest developments and case presentations

18.00

End of course

16.30

S. Schmitz-Valckenberg GERMANY
Autofluorescence image acquisition: Techniques, pearls and pitfalls

16.45

F. Holz GERMANY
Causes of reduced and increased autofluorescence signals: A practical approach

17.00

A. Tufail UK
Findings and prognostic relevance of AF in wet AMD

17.15

M. Fleckenstein GERMANY
Autofluorescence in early and late dry AMD and SD-OCT correlates

17.30

T. Theelen THE NETHERLANDS
Autofluorescence in macular and retinal dystrophies

17.45

Case presentations and discussion

18.00

End of course

16.30

A. Laidlaw UK
Introduction

16.32

L. Downey UK
Pathology and pathophysiology of proliferative retinopathy

16.43

M. Mohamed UK
Proliferative retinopathy

16.54

S. Mann UK
Incidence of vitrectomy in PDR

17.16

T. W illiamson UK
Tractional retinal detachment

17.27

A. Laidlaw UK
Vitrectomy in florid proliferation, use of anti-VEGF agents prior to diabetic vitrectomy

17.38

T. W illiamson UK
Complications of diabetic vitrectomy

17.49

A. Laidlaw UK
Vitrectomy for diabetic macular edema

18.00

End of course